Predicting Response to Anthracyclines in Ovarian Cancer.

Annamaria Ferrero, Martina Borghese, Stefano Restaino, Andrea Puppo, Giuseppe Vizzielli, Nicoletta Biglia

International journal of environmental research and public health 2022 Apr 02

filter terms:

1) Background: Anthracyclines are intriguing drugs, representing one of the cornerstones of both first and subsequent-lines of chemotherapy in ovarian cancer (OC). Their efficacy and mechanisms of action are related to the hot topics of OC clinical research, such as BRCA status and immunotherapy. Prediction of response to anthracyclines is challenging and no markers can predict certain therapeutic success. The current narrative review provides a summary of the clinical and biological mechanisms involved in the response to anthracyclines. (2) Methods: A MEDLINE search of the literature was performed, focusing on papers published in the last two decades. (3) Results and Conclusions: BRCA mutated tumors seem to show a higher response to anthracyclines compared to sporadic tumors and the severity of hand-foot syndrome and mucositis may be a predictive marker of PLD efficacy. CA125 can be a misleading marker of clinical response during treatment with anthracyclines, the response of which also appears to depend on OC histology. Immunochemistry, in particular HER-2 expression, could be of some help in predicting the response to such drugs, and high levels of mutated p53 appear after exposure to anthracyclines and impair their antitumor effect. Finally, organoids from OC are promising for drug testing and prediction of response to chemotherapy.

Citation

Annamaria Ferrero, Martina Borghese, Stefano Restaino, Andrea Puppo, Giuseppe Vizzielli, Nicoletta Biglia. Predicting Response to Anthracyclines in Ovarian Cancer. International journal of environmental research and public health. 2022 Apr 02;19(7)